 ANDOVER, Mass., April 6, 2021 PRNewswire -- TransMedics Group, Inc. TransMedics Nasdaq: TMDX, a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after the review of TransMedics clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol CAP results, as well as the OCS Heart PROCEED II trial, the Circulatory Systems Device Advisory Panel convened by the U.S. Food and Drug Administration FDA has issued a favorable vote in support of approval of the OCS Heart System to the FDAs Office of Health Technology 2 Cardiovascular Devices. 